India, Sept. 28 -- High cholesterol is one of those problems that most people know about and far fewer manage well. Statins are the first line of defence, but many patients at high cardiovascular risk still cannot bring their LDL cholesterol down to the levels doctors want. That gap has opened the door for newer injectable therapies. For drug makers, it has also become a race to find the right products and the right partners to take them to patients in every region.

Shares of Sun Pharmaceutical Industries Ltd. were trading at Rs. 1,844.20, down 0.43 percent from previous close of Rs. 1,852.20. The stock opened at Rs. 1,844,.00, reaching an intraday high of Rs. 1,855.00 and low of Rs. 1,839.10. The company currently has a market capitali...